Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824161 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
A Phase 2 study, sponsored by Taiho Pharmaceutical Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00824161 is a Phase 2 study that was terminated before completion, run by Taiho Pharmaceutical Co.. The registered enrollment target is 28 participants.
The verdict
NCT00824161, a Phase 2 study, was terminated before completion, sponsored by Taiho Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
Interventions
- DRUG TAS-109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824161
The ClinicalTrials.gov registry entry for NCT00824161 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Pharmaceutical Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-109 is the first listed.
NCT00824161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00824161 about?
NCT00824161 is a clinical study titled "Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer". The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
What is the current status of trial NCT00824161?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00824161?
The interventions under investigation include: TAS-109 (DRUG).
Who is sponsoring clinical trial NCT00824161?
This trial is sponsored by Taiho Pharmaceutical Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.